Management of Atrial Flutter
Acute Management
- The American Heart Association recommends beta blockers, diltiazem, or verapamil as first-line agents for acute rate control in hemodynamically stable patients with atrial flutter 1, 3
- In patients with systolic heart failure where beta blockers are contraindicated or ineffective, intravenous amiodarone can be used for acute rate control 1
- Higher doses of rate control medications are often needed in atrial flutter compared to atrial fibrillation due to paradoxically faster AV nodal conduction 2
- The American College of Cardiology recommends avoiding beta blockers, diltiazem, and verapamil in patients with pre-excited atrial flutter due to risk of accelerated ventricular rates and ventricular fibrillation 2
- Synchronized cardioversion is recommended for hemodynamically unstable patients 3
- Elective synchronized cardioversion is indicated in stable patients when pursuing rhythm control 3, 4
- Intravenous ibutilide is effective for acute pharmacological cardioversion 5
- Rapid atrial pacing is useful for acute conversion in patients with pacing wires already in place 3
Anticoagulation
- Anticoagulation recommendations for atrial flutter are the same as for atrial fibrillation 1, 2, 3
- For flutter lasting <48 hours in low-risk patients, anticoagulation should be started before or immediately after cardioversion 4
- For flutter lasting ≥48 hours or unknown duration, anticoagulation should be given for at least 3 weeks before cardioversion or a transesophageal echocardiogram should be performed to exclude thrombus 6
- Following cardioversion, anticoagulation should be continued for at least 4 weeks 4, 6
- Long-term anticoagulation decisions should be based on the patient's thromboembolic risk profile using the same criteria as for atrial fibrillation 2, 3
Long-term Management
- Catheter ablation of the CTI is highly effective (>90% success rate) for typical atrial flutter and is the preferred long-term management strategy 1, 5
- The European Society of Cardiology recommends catheter ablation for recurrent symptomatic non-CTI-dependent flutter after failure of at least one antiarrhythmic drug 2
- Catheter ablation is reasonable as primary therapy for recurrent symptomatic non-CTI-dependent flutter before trials of antiarrhythmic drugs 5
- If catheter ablation is not an option, amiodarone, dofetilide, and sotalol can be useful to maintain sinus rhythm 2, 5
- Flecainide or propafenone may be considered in patients without structural heart disease 5
Special Considerations
- The American College of Cardiology recommends avoiding AV nodal blocking agents in patients with pre-excited atrial flutter 7, 8
- Direct current cardioversion is recommended for patients with pre-excitation and hemodynamic instability 4
- The risk of stroke in patients with atrial flutter is similar to that in atrial fibrillation, with thromboembolism rates averaging 3% annually 1
- Meta-analysis of 13 studies reported short-term stroke risks ranging from 0% to 7% in patients undergoing cardioversion of atrial flutter 1
Common Pitfalls and Caveats
- Rate control can be more difficult to achieve in atrial flutter than in atrial fibrillation 2
- Conversion of atrial flutter to atrial fibrillation may occur with antiarrhythmic drugs 1
- When using class IC antiarrhythmic drugs for rhythm control, concomitant AV nodal blocking drugs should be administered to prevent rapid ventricular rates if flutter occurs 7